Home › Trials › NCT06857942

Investigating the effectiveness of tirzepatide added to ixekizumab for psoriasis and obesity

A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice

Phase 4 Interventional Eli Lilly and Company · NCT06857942

This study is testing if adding a weight-loss medication called tirzepatide to an existing psoriasis treatment can help people with moderate-to-severe plaque psoriasis who are also overweight or obese.

Quick facts

PhasePhase 4
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company Industry-sponsored
Drugs / interventionsixekizumab
Locations43 sites (Phoenix, Arizona and 42 other locations)
Trial IDNCT06857942 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate how effective the addition of tirzepatide is when used alongside ixekizumab in patients with moderate-to-severe plaque psoriasis who are also overweight or obese. Participants must have been on ixekizumab for about three months before starting tirzepatide. The study will last for up to 12 months and will take place in standard clinical practice settings. The focus is on patients who have at least one weight-related comorbidity.

Who should consider this trial

Good fit: Ideal candidates are individuals diagnosed with moderate-to-severe plaque psoriasis and a BMI of 27 or greater, who have been on ixekizumab for approximately three months.

Not a fit: Patients who have been on ixekizumab for more than four months or have previously used tirzepatide or similar medications may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could improve treatment outcomes for patients with psoriasis and obesity, potentially leading to better management of both conditions.

How similar studies have performed: While this specific combination has not been extensively tested, similar approaches using other GLP-1 receptor agonists have shown promise in managing obesity-related conditions.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)
* Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).
* Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide.
* Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).

Exclusion Criteria:

* Have currently received ixekizumab for more than 4 months or less than 2 months.
* Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.
* Are currently enrolled in any other clinical study.

Other exclusions

* Have a known hypersensitivity to tirzepatide or to any of its component.
* Have a personal or family history of medullary thyroid cancer.
* Have multiple endocrine neoplasia type 2.
* Have type I diabetes mellitus.
* Have a history of chronic or acute pancreatitis at any time before screening (Visit 1).
* Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.
* Have a history of ketoacidosis or hyperosmolar state/coma.
* Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.
* Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.

Where this trial is running

Phoenix, Arizona and 42 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions PsoriasisOverweight or Obesity
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.